Expert consensus on quality control indicators for integrative medicine in rheumatoid arthritis (2023 version)

Abstract

The rising costs of cancer care and subsequent medical financial hardship for cancer survivors and families are well documented in the United States. Less attention has been paid to employment disruptions and loss of household income after a cancer diagnosis and during treatment, potentially resulting in lasting financial hardship, particularly for working-age adults not yet age-eligible for Medicare coverage and their families. In this article, the authors use a composite patient case to illustrate the adverse consequences of cancer diagnosis and treatment for employment, health insurance coverage, household income, and other aspects of financial hardship. They summarize existing research and provide nationally representative estimates of multiple aspects of financial hardship and health insurance coverage, benefit design, and employee benefits, such as paid sick leave, among working-age adults with a history of cancer and compare them with estimates among working-age adults without a history of cancer from the most recently available years of the National Health Interview Survey (2019–2021). Then, the authors identify opportunities for addressing employment and health insurance coverage challenges at multiple levels, including federal, state, and local policies; employers; cancer care delivery organizations; and nonprofit organizations. These efforts, when informed by research to identify best practices, can potentially help mitigate the financial hardship associated with cancer.

Keywords

indicators / integrated Chinese and Western medicine / medical quality / rheumatoid arthritis

References

[1] Firestein GS , McInnes IB . Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017; 46 (2): 183- 196.

[2] Li ZG , Tang FL . Kelley’s Textbook of Rheumatology. 8th ed. Peking University Medical Press; 2011: 1133.

[3] Sparks J . Rheumatoid Arthritis. Ann Intern Med. 2019; 170 (1): ITC1- ITC16.

[4] Jin S , Li M , Fang Y , et al. Chinese Registry of Rheumatoid Arthritis (CREDIT): Ⅱ. Prevalence and Risk Factors of Major Comorbidities in Chinese Patients with Rheumatoid Arthritis. Arthritis Res Ther. 2017; 19 (1): 251.

[5] van der Woude D , van der Helm Mil AHM . Update on the Epidemiology, Risk Factors, and Disease Outcomes of Rheumatoid Arthritis. Best Pract Res Clin Rheumatol. 2018; 32 (2): 174- 187.

[6] Zeng XF , Zhu SL , Tan AC , Xie XP . Disease Burden and Quality of Life of Rheumatoid Arthritis in China: A Systematic Review. Chin J Evid-based Med. 2013; 13 (03): 300- 307.

[7] Zhou YS , Wang XR , An Y , et al. A Multicenter Study of Deformity and Disability in Rheumatoid Arthritis Patients in China. Chin J Rheumatol. 2013; 17 (8): 526- 532.

[8] Cross M , Smith E , Hoy D , et al. The Global Burden of Rheumatoid Arthritis: Estimates from the Global Burden of Disease 2010 Study. Ann Rheum Dis. 2014; 73 (7): 1316- 1322.

[9] Xavier RM , Zerbini CAF , Pollak DF , et al. Burden of Rheumatoid Arthritis on Patients’ Work Productivity and Quality of Life. Adv Rheumatol. 2019; 59 (1): 47.

[10] Gil-Conesa M , Del-Moral-Luque JA , Gil-Prieto R , Gil-de-Miguel Á , Mazzuccheli-Esteban R , Rodríguez-Caravaca G . Hospitalization Burden and Comorbidities of Patients with Rheumatoid Arthritis in Spain during the Period 2002-2017. BMC Health Serv Res. 2020; 20 (1): 374.

[11] Kong XY , Wen CP . On Research Progress of Western and Chinese Medicine Treatment on Pre-rheumatoid Arthritis. Chin J Integr Med. 2019; 25 (9): 643- 647.

[12] Zhang L , Cao Z , Yang Y , Tan X , Mao J , Su L . Traditional Chinese Medicine on Treating Active Rheumatoid Arthritis: A Protocol for Systematic Review and Meta-Analysis. Medicine (Baltim). 2020; 99 (24): e20642.

[13] Tao QW , Wang JP , XuY WJM , Zhang YZ . Expert Consensus on Quality Control Indicators for Integrative Medicine in Rheumatoid Arthritis (2021 Version). J China-Jpn Friendsh Hosp. 2021; 35 (01): 12- 15.

[14] Paalanen K , Puolakka K , Nikiphorou E , Hannonen P , Sokka T . Is Seronegative Rheumatoid Arthritis True Rheumatoid Arthritis? A Nationwide Cohort Study. Rheumatology. 2021; 60 (5): 2391- 2395.

[15] Qu P , Wang H , Wang W , et al. Efficacy and Safety of Duhuo-Jisheng Decoction in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of 42 Randomized Controlled Trials. Medicine (Baltim). 2023; 102 (44): e35513.

[16] Wang F , Liu J , Fang Y , Li X , He M , Han Q . Traditional Chinese Medicine May Be Associated with a Reduced Risk of Recurrent Exacerbation in Patients with Rheumatoid Arthritis: A Matched Cohort Study Based on 1383 Individuals. Heliyon. 2023; 9 (4): e15054.

[17] Smolen JS . Treat-to-target as an Approach in Inflammatory Arthritis. Curr Opin Rheumatol. 2016; 28 (3): 297- 302.

[18] Shi LJ , Li SG . Treating Rheumatoid Arthritis to Target: Choosing and Evaluating the Target. Chin J Rheumatol. 2020; 24 (06): 361- 363.

[19] Zhang YL , Ma GQ , Zhao J , et al. Analysis of Big Data and Strategy Research on Medical Safety (Adverse) Events in China. Chinese Hospit Manag. 2020; 40 (8): 29- 32.

[20] Ru J , Ma J , Niu H , et al. Burden and Depression in Caregivers of Patients with Rheumatoid Arthritis in China. Int J Rheum Dis. 2019; 22 (4): 608- 613.

[21] Bai B , Chen M , Fu L , et al. Quality of Life and Influencing Factors of Patients with Rheumatoid Arthritis in Northeast China. Health Qual Life Outcome. 2020; 18 (1): 119.

[22] Yang Y , Yang J , Li HJ , et al. Analysis of Self-Perceived Burden and Related Factors in Patients with Rheumatoid Arthritis. J Lanzhou Univ. 2019; 45 (3): 91- 96.

[23] Li YT , Jiang Q , Gong X , et al. Status Investigation and Analysis on Traditional Chinese Medicine Treatment in Rheumatoid Arthritis Patients. J Tradit Chin Med. 2020; 61 (8): 676- 680.

[24] Li ZX , Xie XP , Miao HL , Zhang JY , Xue HY . Analysis of Status Quo and Influencing Factors of Continuous Nursing Quality of Patients with Rheumatoid Arthritis. Chin Nurs Res. 2020; 34 (22): 4072- 4076.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Advanced Chinese Medicine published by John Wiley & Sons Australia Ltd on behalf of Higher Education Press.